The proposed filling line is expected produce up to 1 million units per day and is well suited for the aseptic filling of high-volume products, like vaccines.
The company also plans to increase its services for the early clinical phases of new drugs in its Vetter Development Service locations in Chicago and Ravensburg.
The company provides a wide range of services that includes formulation support and customised packaging development.
Vetter anchors its position as a partner for the development and commercial manufacturing of parenteral drugs.
The company’s know-how in process- and packaging development in aseptic filling is used to support professional clinical offering.
Vetter Managing Director Peter Soelkner said,"In the area of prefilled syringes we provide our partners a full range of service, from small batches manufacturing and support in early clinical stages to high-volume manufacturing for large scale commercial production."